| |
April 3-4, 2023 | San Diego, CA The only west coast event exclusively for life science communicators to share best practices, benchmarks, and tools, as well as network with peers. Early Bird Rate Ends January 27th.
|
|
Today's Big NewsJan 23, 2023 |
| By Andrea Park Prosecutors have asked a judge not to allow convicted Theranos founder Elizabeth Holmes to stay out of prison during her upcoming appeal process, citing an instance ahead of her sentencing last year where she appeared to be preparing to flee the U.S. |
|
|
|
By Fraiser Kansteiner After Republicans wrested control of the House of Representatives in November, threats of wide-ranging probes into President Joe Biden and his administration quickly followed. Now, Democrats—holding the reins of the Senate—are firing a return salvo, and the pharmaceutical industry will likely rank among the victims, Bloomberg reports. |
By Max Bayer Merck KGaA is laying off roughly 11% of its U.S. outpost, shrinking a Massachusetts R&D unit by more than 130 employees. The cuts come two months after executives revealed a push to be a leaner organization. |
By Heather Landi Discount retailer Dollar General is expanding into healthcare services in what could be a competitive shot across the bow for drugstores. The company is piloting mobile health clinics at three stores in Tennessee to provide customers with basic, preventive and urgent care services along with lab testing. |
|
Thursday, February 16, 2023 | 11am ET / 8am PT Join this session as a panel of experts discusses the realized benefits of using AI and communication tools to redefine the care pathway to detect stroke and streamline the patient journey to direct more patients for cardiology follow-up. Register now.
|
|
By Kevin Dunleavy Since the start of the decade, big pharma companies from Europe and the United States have descended on China to get in on the country’s biotech boom. The latest big pharma player to get a piece of the action however is closer to home. Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. |
By Max Bayer A brutal year for biotech has private investors eyeing bets with less risk and more emphasis on single assets over drug discovery engines, but there's plenty of optimism to go around in the opening weeks of 2023. |
By Andrea Park Insulet has issued an alert for a data breach that may have compromised the health data of thousands of users of its Omnipod Dash insulin pumps. |
By Frank Diamond Workers with diabetes enrolled in high-deductible health plans face a much greater risk of being rushed to emergency departments because of hyperglycemia, says a new study. Employers need to be more judicious when weighing whether to shift employees into HDHPs. |
By Andrea Park Much like its ancient Greek namesake, a new artificial intelligence tool dubbed Sybil may be able to see into the future—though its predictions are delivered to doctors rather than to mythical gods. |
By Nick Paul Taylor Morphic Therapeutic has lost another Big Pharma partner. Eleven months after AbbVie walked away, Johnson & Johnson has delivered the killer blow to its own already-diminishing ties to the biotech. |
By Dave Muoio New reports outline trends among new CEO appointments and increasing pressure for those at the helm of hospitals and health systems. |
By Ben Adams Novartis has pulled questionable efficacy claims in a direct-to-consumer ad campaign for its breast cancer drug Kisqali after the National Advertising Division (NAD) ruled they didn’t stack up, though similar claims made to healthcare professionals can stay. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk and addressing the specific drug supply challenges commonly associated with adaptive, decentralized, platform and other complex trial designs. Register now.
|
|
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
